| Literature DB >> 33458694 |
Olga Lancho1, Jui-Wan Loh1,2, Amartya Singh1,2, Shunsuke Kimura3, Luca Tottone1, Juliette Roels4,5,6, Anna Kuchmiy5,6, Steven Strubbe5,6, Matthew A Lawlor1, Victoria da Silva-Diz1, Shirley Luo1, Stéphanie Gachet7, Carlos A García-Prieto8,9, Rico Hagelaar10, Manel Esteller8,11,12,13, Jules P P Meijerink10, Jean Soulier7, Tom Taghon5,6, Pieter Van Vlierberghe4,5, Charles G Mullighan3, Hossein Khiabanian1,2,14, Pedro P Rocha15,16, Daniel Herranz17,18.
Abstract
Long-range oncogenic enhancers play an important role in cancer. Yet, whether similar regulation of tumor suppressor genes is relevant remains unclear. Loss of expression of PTEN is associated with the pathogenesis of various cancers, including T-cell leukemia (T-ALL). Here, we identify a highly conserved distal enhancer (PE) that interacts with the PTEN promoter in multiple hematopoietic populations, including T-cells, and acts as a hub of relevant transcription factors in T-ALL. Consistently, loss of PE leads to reduced PTEN levels in T-ALL cells. Moreover, PE-null mice show reduced Pten levels in thymocytes and accelerated development of NOTCH1-induced T-ALL. Furthermore, secondary loss of PE in established leukemias leads to accelerated progression and a gene expression signature driven by Pten loss. Finally, we uncovered recurrent deletions encompassing PE in T-ALL, which are associated with decreased PTEN levels. Altogether, our results identify PE as the first long-range tumor suppressor enhancer directly implicated in cancer.Entities:
Keywords: NOTCH1; PTEN; T-ALL; T-cell acute lymphoblastic leukemia; enhancer
Mesh:
Substances:
Year: 2020 PMID: 33458694 PMCID: PMC7810363 DOI: 10.1158/2643-3230.BCD-20-0201
Source DB: PubMed Journal: Blood Cancer Discov ISSN: 2643-3230